Loading quotes...
Forecast
There is no analyst data available for this company.
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Historical dividends Dividends
All dividend metrics All metricsFinancials
| (EUR) | March 2026 | YoY |
|---|---|---|
| Revenue | 69.99M | - |
| Gross profit | 30.48M | - |
| Net profit | 5.72M | - |
| EBITDA | 10.7M | - |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €231.52M |
Number of shares | 104.87M |
52-week high/low | €2.53 - €1.66 |
Dividend yield | 0.66% |
Dividends TTM | €0.0147 |
Beta | 0.43 |
P/E ratio | 31.97 |
PEG ratio | 1.92 |
P/B ratio | 4.30 |
P/S ratio | 1.86 |
Company profile
AFT Pharmaceuticals Limited, together with its subsidiaries, engages in the development and sale of pharmaceutical products in New Zealand, Australia, Asia, and internationally. It offers products for use in the areas of allergy, cold and flu, digestive health, eye care, first aid, nail care, oral care, pain management, skin care, and supplements, as well as other products. AFT Pharmaceuticals Limited was incorporated in 1997 and is headquartered in Auckland, New Zealand.
| Name | AFT PHARMACEUTICAL LTD |
| CEO | Hartley Atkinson |
| Headquarters | Auckland,
auk New Zealand |
| Website | |
| IPO | 12/21/2015 |
| Employees | 126 |
Ticker symbols
| Exchange | Symbol |
|---|---|
Nze | AFT.NZ |
Australian Securities Exchange Ltd | AFP.AX |